Menu Search
Equities

Masimo Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
3M4:FRA

Masimo Corp

Actions
  • Price (EUR)138.60
  • Today's Change-3.50 / -2.46%
  • Shares traded5.00
  • 1 Year change+35.95%
  • Beta1.2168
Data delayed at least 15 minutes, as of Jul 11 2025 20:38 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Masimo Corporation is a global technology company that develops, manufactures and markets a wide array of patient monitoring technologies, as well as automation and connectivity solutions. The Company's segments include healthcare and non-healthcare. The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. The Company primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities and consumers. Its measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry and advanced rainbow Pulse CO-Oximetry parameters. The Company’s non-healthcare consumer business incorporates audio and home integration technologies that are primarily sold or licensed directly to consumers, or through authorized retailers and wholesalers.

  • Revenue in USD (TTM)1.97bn
  • Net income in USD-276.60m
  • Incorporated1996
  • Employees3.60k
  • Location
    Masimo Corp52 DiscoveryIRVINE 92618United StatesUSA
  • Phone+1 (949) 297-7000
  • Fax+1 (949) 297-7499
  • Websitehttps://www.masimo.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.